Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 6/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7018972 | 0.91 | GRIN1 (0.44) | GRIN1GRIN2BMMP13SLC22A8 | |
| SCHEMBL7103058 | 0.90 | MMP13 (0.47) | MMP13SLC22A8P2RX3 | |
| SCHEMBL7018710 | 0.89 | MMP13 (0.46) | MMP13SLC22A8 | |
| SCHEMBL7022157 | 0.86 | MAPT (0.53) | MMP13SLC22A8CCR2 | |
| SCHEMBL6255569 | 0.85 | MMP13 (0.53) | MMP13SLC22A8 | |
| SCHEMBL7097739 | 0.84 | MMP13 (0.46) | MMP13SLC22A8MAPK1 | |
| SCHEMBL7097608 | 0.84 | MAPT (0.47) | GRIN1GRIN2BMMP13SLC22A8 | |
| SCHEMBL7012164 | 0.82 | MMP13 (0.56) | MMP13SLC22A8CCR2 | |
| SCHEMBL7100732 | 0.82 | PIK3CD (0.51) | MMP13SLC22A8PDE1BMAPK1 | |
| SCHEMBL7014083 | 0.80 | MAPK1 (0.55) | MMP13SLC22A8MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368324-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | disclosed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | GRIN1 2546/4885GRIN2B 2437/4885MMP13 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.